• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Use of atezolizumab in bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.阿替利珠单抗在卡介苗无反应的高危非肌层浸润性膀胱癌中的应用。
Transl Androl Urol. 2024 Jun 30;13(6):1061-1063. doi: 10.21037/tau-23-630. Epub 2024 May 24.
2
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.atezolizumab 在卡介苗无应答高危非肌肉浸润性膀胱癌中的 2 期临床试验：SWOG S1605。
Eur Urol. 2023 Dec;84(6):536-544. doi: 10.1016/j.eururo.2023.08.004. Epub 2023 Aug 16.
3
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.阿特珠单抗单药或联合卡介苗用于高危非肌肉浸润性膀胱癌患者的 1b/2 期研究。
Eur Urol Oncol. 2023 Jun;6(3):313-320. doi: 10.1016/j.euo.2023.01.013. Epub 2023 Feb 15.
4
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.CREST 研究：sasanlimab 联合卡介苗治疗卡介苗初治高危非肌层浸润性膀胱癌患者的 III 期临床研究。
Future Oncol. 2024 May;20(14):891-901. doi: 10.2217/fon-2023-0271. Epub 2024 Jan 8.
5
Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer.免疫疗法在卡介苗无反应性非肌肉浸润性膀胱癌中的作用
Transl Cancer Res. 2020 Oct;9(10):6537-6545. doi: 10.21037/tcr-20-758.
6
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.卡介苗无反应性非肌层浸润性膀胱癌患者的膀胱保留治疗：长期生存结果分析
Eur Urol Open Sci. 2023 May 13;53:16-22. doi: 10.1016/j.euros.2023.04.013. eCollection 2023 Jul.
7
Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.评估卡介苗膀胱灌注与根治性膀胱切除术对英国高危非肌层浸润性膀胱癌患者的成本效益。
J Med Econ. 2023 Jan-Dec;26(1):411-421. doi: 10.1080/13696998.2023.2189860.
8
Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.成纤维细胞生长因子受体改变对卡介苗免疫治疗和非卡介苗免疫治疗的高级别非肌肉浸润性膀胱癌的预后和预测价值。
Eur Urol. 2022 Jun;81(6):606-614. doi: 10.1016/j.eururo.2022.02.028. Epub 2022 Mar 26.
9
Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.经卡介苗膀胱内灌注后非肌层浸润性膀胱癌的膀胱保留治疗疗效的系统评价
Eur Urol. 2020 Sep;78(3):387-399. doi: 10.1016/j.eururo.2020.02.012. Epub 2020 Mar 4.
10
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌（TaT1 和原位癌）指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.

引用本文的文献

1
Balancing risks and benefits in the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer.卡介苗无反应性高危非肌层浸润性膀胱癌患者治疗中风险与获益的平衡
Transl Androl Urol. 2025 Jan 31;14(1):1-3. doi: 10.21037/tau-24-529. Epub 2025 Jan 16.

本文引用的文献

1
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.atezolizumab 在卡介苗无应答高危非肌肉浸润性膀胱癌中的 2 期临床试验：SWOG S1605。
Eur Urol. 2023 Dec;84(6):536-544. doi: 10.1016/j.eururo.2023.08.004. Epub 2023 Aug 16.
2
Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer.高危非肌肉浸润性膀胱癌的新型治疗方法。
Curr Oncol Rep. 2023 Feb;25(2):83-91. doi: 10.1007/s11912-022-01350-9. Epub 2022 Dec 26.
3
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.NCCN 指南®洞察：膀胱癌，第 2.2022 版。
J Natl Compr Canc Netw. 2022 Aug;20(8):866-878. doi: 10.6004/jnccn.2022.0041.
4
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.帕博利珠单抗单药治疗卡介苗（BCG）无应答的高风险非肌肉浸润性膀胱癌（KEYNOTE-057）：一项开放标签、单臂、多中心、2 期研究。
Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26.
5
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.纳武拉非尼基因导管治疗卡介苗无应答性非肌肉浸润性膀胱癌：一项单臂、开放标签、重复剂量临床试验。
Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27.
6
KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC.KEYNOTE-676：卡介苗和帕博利珠单抗用于持续性/复发性高危非肌层浸润性膀胱癌的 III 期研究。
Future Oncol. 2020 Apr;16(10):507-516. doi: 10.2217/fon-2019-0817. Epub 2020 Mar 12.
7
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.CG0070溶瘤病毒方案治疗卡介苗无反应性非肌层浸润性膀胱癌患者安全性和有效性的开放标签、单臂、II期多中心研究：中期结果
Urol Oncol. 2018 Oct;36(10):440-447. doi: 10.1016/j.urolonc.2017.07.005. Epub 2017 Jul 26.
8
CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.CG0070，一种条件性复制的粒细胞巨噬细胞集落刺激因子武装的溶瘤腺病毒，用于治疗膀胱癌。
Clin Cancer Res. 2006 Jan 1;12(1):305-13. doi: 10.1158/1078-0432.CCR-05-1059.

Use of atezolizumab in bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.

作者信息

Akinsola Olutiwa A, Talwar Ruchika, Baskin Avi, Luckenbaugh Amy N, Al Hussein Al Awamlh Bashir

机构信息

Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.

Department of Urology, Weill Cornell Medicine, New York, NY, USA.

出版信息

Transl Androl Urol. 2024 Jun 30;13(6):1061-1063. doi: 10.21037/tau-23-630. Epub 2024 May 24.

DOI:10.21037/tau-23-630
PMID:38983471
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11228680/
Abstract
摘要